Mrs. Lori Anne Mezeivtch is a pharmacist who is specialized in Pharmacotherapy in Pittsburgh, Pennsylvania. Patients can reach her at 3601 5th Ave, Pittsburgh or contact her on 412-647-3244. Active license number of Mrs. Lori Anne Mezeivtch is RP040921L for Pharmacotherapy in Pennsylvania. Mrs. Lori Anne Mezeivtch is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Mrs. Lori Anne Mezeivtch speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mrs. Lori Anne Mezeivtch are as mentioned below.
NPI Number:
1962539676
NPI Enumeration Date:
28 Feb, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mrs. Lori Anne Mezeivtch are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
RP040921L
Pennsylvania
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
4962 Carlyn Dr, Pittsburgh, Pennsylvania
Zip:
15236-1944
Phone Number:
412-885-0460
Fax Number:
412-647-7951
Patients can reach Mrs. Lori Anne Mezeivtch at 3601 5th Ave, Pittsburgh, Pennsylvania or can call on phone at 412-647-3244.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.